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The value of antihypertensive therapy in patients with malignant hyperten- 
sion has been well established (1, 2).  In  patients with less severe hypertension 
the mortality is reduced, mainly due to the decreased incidence of cerebral hemor- 
rhage. This may be reflected in the decreasing mortality rate from stroke in the 
United States (3-6). However, the value of antihypertensive therapy for the 
treatment of moderate hypertension is not established, and its place in the treat- 
ment of cerebrovascular disease is hotly contended (7, 8 ) .  One retrospective 
review (9) of clinical records on patients treated for hypertension showed that 
in 80 patients who had experienced satisfactory reduction of blood pressure for 
a 68-month period there was no development of cerebral thrombosis, embolism 
or hemorrhage, whereas in 13 patients with similar initial high blood pressures 
followed for a comparable period, the blood pressure rose slightly and strokes 
developed. 
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In  another study (10) a comparison of 39 treated hypertensive patients with 
42 untreated patients revealed that after three years of therapy with various 
antihypertensive drugs, the treated patients were similar in many respects to 
the untreated ones. Over the three-year period, however, the survival rate 
was 90 per cent in the treated group, with 2 fatal and 8 non-fatal strokes; in 
the untreated group the rate was 66 per cent, with 6 fatal and 22 non-fatal 
strokes. In  a different study (11) of patients with diastolic hypertension in the 
range of 110 mm Hg or more, the subjects were assigned alternately to a group 
treated with antihypertensive drugs or to a control group that received no treat- 
ment for hypertension. Over a period of two to six years there were 4 strokes 
among the 30 treated subjects and 7 strokes among the 31 who were untreated. 
Recently, a prospective study (12) was completed on 87 asymptomatic pa- 
tients with moderate hypertension, some of whom were already receiving hypo- 
tensive drugs. On the basis of random drawing, half the patients were treated 
with antihypertensive agents and half were treated with matched placebos ; some 
also received thiazides for congestive heart failure. In  the treated group there 
was an adequate fall in blood pressure. In  twenty-two months there were 2 
strokes in the treated group and 1 stroke in the control group. 
This brief review summarizes the presently available knowledge concerning 
the relationship between stroke and hypertension and suggests that control 
of moderate hypertension may prevent cerebrovascular hemorrhage, embolism 
and thrombosis. However, the value of controlling hypertension in subjects 
with moderate hypertension and cerebrovascular symptoms is by no means 
established and there is some evidence that lowering the blood pressure in such 
persons may make transient cerebrovascular symptoms worse. 
These considerations led us to design a double-blind study of the use of 
antihypertensive therapy in patients with known cerebrovascular disease associ- 
ated with moderate hypertension. 
DESIGN OF STUDY 
The patients were drawn from the Wayne County General Hospital, from the Hyper- 
tension Unit of the University of Michigan School of Medicine, and from the neurology 
clinics of the Detroit General Hospital and the Wayne Center for Cerebrovascular Re- 
search at Harper Hospital. 
Selection of patients 
The patients were admitted to the study if they had a permanent cerebrovascular 
deficit (cerebral thrombosis, hemorrhage or embolism) and/or a transient cerebrovas- 
cular deficit or transient ischemic attacks (TIA) within the preceding twelve months. 
The blood pressure had to be in the range of 150 to 200 mm Hg systolic and 90 to 120 
mm diastolic. This was determined by review of the clinic records. Transient ischemic 
attacks were defined as episodes of definite focal neurologic deficit clearing entirely 
within twenty-four hours. There were no age limits. Subjects recently treated with 
hypotensive medication whose blood pressures were in the normal range were included 
in the study if there was a well documented history of pre-treatment hypertension meet- 
ing the requirements of the study. 
The distribution of the 32 treated and control patients with respect to age, sex, race 
and duration of observation is shown in Table 1. 
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TABLE 1 
Antihypertensive Drug Placebo 
Number of patients 
Months in study (mean) 
Age (mean, yrs.) 
Sex and Race: 
Negro males 
Negro females 
White males 
White females 
17 
9.7 
57.7 
15 
11.1 
46.5 
Pre-treatment evaluation 
All subjects had a complete neurologic examination. With rare exceptions, the cere- 
brospinal fluid was examined for pressure, cellular content, protein content and sero- 
logic reactions for syphilis. Roentgenograms of the skull and electroencephalograms 
were also routinely obtained. The patients were admitted to the hospital a t  the begin- 
ning of the study and complete cerebral arteriograms were performed, with the exception 
of a few subjects who entered the study from the out-patient clinic. Cerebral radio- 
isotope studies (radioactive mercury) were made in many cases. Determinations of 
blood urea nitrogen, uric acid, two-hour postprandial glucose and serologic reactions 
for syphilis were routinely made and repeated if necessary. When the subject was 
found suitable for the study, a two-week trial of the hypotensive medication was started 
and a one-page description was sent to the other participating investigators for their 
review. If it was unanimously agreed that the subject be accepted, he was assigned, in 
random manner, to either the treatment or the control group. 
T h e  controlled therapeutic program 
After a satisfactory two-week therapeutic trial, a table of random numbers was used 
by the statistical consultant' to divide the patients into the two groups (treatment and 
control). This choice was not known to members of the study. 
The treatment group received 1 tablet twice daily of the active drug which contained 
0.5 mg of deserpidine and 5.0 mg of methyclothiazide.2 The control group received one 
placebo tablet of identical appearance, twice daily. In the treated group, the aim was 
to control the systolic blood pressure (standing position) at  a level of 140-160 mm Hg, 
with the use of 2 tablets daily. Medication was reduced to 1 tablet daily if the systolic 
pressure dropped below 110 mm; then the previous dosage was resumed once the blood 
pressure rose above that level. The subjects were examined at  monthly intervals. The 
blood pressures were checked by three recordings with the patient in the standing 
position and three recordings with the patients in the supine position after a fifteen- 
minute rest. Initially, the blood pressures were checked in both arms; then the arm 
showing the higher reading was used for subsequent recordings. All pressures were re- 
corded with the sphygmomanometer cuff at  the level of the heart. 
Neurologic evaluation for cerebrovascular symptoms 
Every three months, or a t  any time when a patient reported a change in neurologic 
status, a complete neurologic examination was carried out. A neurologic scoring sheet 
was Bled out; the graded scores ranged from 0 (death) to 100 (normal). This rating 
system placed strong emphasis on mental and performance status. Any subject was 
' Dr. Richard Remington, School of Public Health, University of Michigan. 
a Enduronyl-Forte, Abbott Laboratories, North Chicago, Ill. 
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withdrawn from the study if new cerebrovascular symptoms occurred with a neuro- 
logic deficit lasting more than twenty-four hours, or an incapacitating transient cerebral 
ischemic attack (TIA). Another cause for withdrawing a subject from the study was 
a rise in blood pressure above the study limits for two consecutive visits; the patient 
was then treated. This was an ethical decision in order to protect the patients from the 
known deleterious effects of severe hypertension. Only subjects with neurologic deficits 
were considered when the data were analyzed. 
RESULTS 
Table 1 shows the mean duration of observation for the treated and control 
groups. One patient was dropped from the study after eight months because of 
dangerously elevated blood pressure. The similarity of the initial blood pressure 
in the two groups and the values for the average blood pressure after three 
months of study are shown in Table 2. Resting blood pressures (patient 
supine) were used for all charts. 
Table 3 shows the changes in mean blood pressure after seven months, and 
the clinical status a t  that time. The patients were divided into three groups: 
Group I, with an average blood pressure of 180/107 mm Hg (mean, 143 mm) . 
Group 11, with moderate hypertension ; average blood pressure 163/105 mm 
Group 111, with mild hypertension; average blood pressure 150/99 mm Hg 
Hg (mean, 134 mm). 
(mean, 125 mm). 
Patients in whom symptoms developed during the study 
Group I, L.D., a treated patient, had a cerebral thrombosis one and a half 
months after entering the study. Severe left hemiparesis, obtundation and 
aphasia developed. Her blood pressure a t  the time of the stroke was 170/104. The 
cerebrospinal fluid was normal. She was admitted to a nursing home. The 
neurologic deficit was still present when she was examined one week later. 
Group I, M.B., a treated patient, had a cerebral thrombosis five months after 
admission to the study. She was hospitalized by her physician but her records 
were made available to us. Her blood pressure was 170/90 on admission, a t  the 
time of right hemiparesis, which cleared after three days. The cerebrospinal 
TABLE 2 
Blood Pressure and Clinical Changes 
Antihypertensive 
Drug Group Placebo Group 
B.P., initial (avge.) 
B.P., 3 months (avge.) 
~~ 
165/102 mm 161/106 mm 
137/83 164/99 
Cerebral thrombosis (No. of cases) 
Worse; more TIA’s 2 
Unchanged 11 
Unchanged but still having TIA’s 
Improved 2 
2 
2 
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Comb. 
TIA 
TABLE 3 
Blood Pressure and Clinical Status after Seven Months of Therapy 
F/52 
M/66 
I 
Group I :  avge. B.P.  180/107; mean B.P.  1.44 
MF (N) Thr. 
MMy (N) TIA 
TIA* 
Thr . 
Thr . 
Thr. 
Thr. 
Thr. 
Comb. 
Thr . 
Thr . 
Thr . 
F/42 130 -9 
F/51 128 -2 
- 
M/59 
M/51 
M/64 
M/38 
M/72 
F/60 
F/61 
M/62 
F/@ 
M/63 
- 
145 +5 
140 -41 
140 +20 
[avge. -5) 
148 -13 
148 -22 
148 -11 
146 -41 
145 -16 
140 4-6 
140 -37 
(avge. -19 
&oup 11: avge. B.P.  166/106; mean B.P.  164 
Thr . 
Thr. 
Thr . 
TIA 
Thr . 
Thr . 
F/78 
M/46 
F/48 
F/41 
F/46 
M/64 
TIA I M/59 
138 +12 
135 -14 
135 -22 
134 +12 
130 +2 
130 +35 
133 -8 
(avge. +1: 
138 -45 
136 -30 
133 -15 
(avge. -3C 
Group III: avge. B.P.  l60/99; mean B.P.  194 
-
lacebo 
heat- 
ment 
or 
- 
P** 
P 
P 
T 
T 
T 
T 
T 
T 
T 
- 
- 
P 
P 
P 
P 
P 
P 
P 
T 
T 
T 
- 
P 
P 
Clinical Status at 7 Months 
Unchanged; occasional TIA’s 
Unchanged 
Unchanged 
Unchanged 
Unchanged 
CVA at 1.5 months; dropped from 
Unchanged; TIA’s in same freq. 
Unchanged 
CVA at 5 months; dropped from 
study 
Unchanged; slightly depressed 
study 
Improved (mentation) 
Unchanged 
Unchanged 
Unchanged; no TIA’s 
Unchanged 
CVA at 7 months; dropped from 
study 
Improved (ambulation) but dropped 
from study at  8 months because 
B.P. rose too high 
Worse due to incr. TIA’s; dropped 
Worse due to incr. TIA’s; dropped 
Unchanged; no TIA’s 
from study at 8 months 
from study a t  2 months 
Improved (mentation and ambula- 
Unchanged; TIA’s in same freq. 
tion) 
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TABLE 3-Continued. 
Initial 
Clinical 
Status 
Vol. xv 
127 -1 
115 +17 
128 -22 
125 -6 
125 -12 
120 +15 
116 +13 
115 -10 
(avge. -4) 
P 
P 
T 
T 
T 
T 
T 
T 
Mean Blood Placebo I ant;;zth 1 Treat- 
ment 
Sex,age Pressure (initial or 
LB (N) 
ss (N) 
V M ( N )  
PT (N) 
CD (N) 
AE (N) 
BH (N) 
NB (N) 
GTOUP 111: avge. B.P. 160/99; mean B.P. 
Thr. 
Thr. 
TIA 
Thr. 
Thr. 
Thr. 
TIA 
Thr. 
F/50 
F/43 
F/42 
F/63 
F/53 
F/67 
F/32 
M/61 
Clinical Status at 7 Months 
Unchanged 
Unchanged 
Improved; no TIA’s 
Unchanged 
Unchanged 
Improved (mentation) 
Unchanged; rare TIA’s 
Unchanged; slightly depressed 
* TIA = Transient ischemic attacks. 
Comb. = Complete stroke plus TIA’s. 
Thr. = Cerebral thrombosis. 
** P = Placebo. 
T = Treatment with antihypertensive drug. 
fluid was not examined. When she was seen a few weeks later in the clinic, she 
had recovered to the level of her neurologic status before entering the study. 
Although she had been taking the active drug, her blood pressure had risen by the 
time of her clinic visit prior to the stroke. 
Group I, E.W. In  this patient, transient ischemic attacks developed dur- 
ing hypotensive therapy. She had attacks of vertigo and ataxia when her blood 
pressure was reduced below 126/88 mm. 
Group 11, M.Mi. was treated with placebo and experienced an episode similar 
to that of M.B.-with full recovery from left hemiparesis after four days. 
Group 11, J.M. and C.L. were patients with vertebro-basilar insufficiency 
manifested by intermittent vertigo and ataxia during active hypertensive 
therapy. Both became symptomatically worse when the blood pressure was 
reduced ; the frequency of transient cerebral ischemic attacks, was greatly in- 
creased and the patients had to remain in bed. They recovered to the level of 
their previous status when the drug was discontinued. 
Group 11, G.Cy. was dropped from the study after eight months of placebo 
therapy because her blood pressure rose to a dangerously high level and was 
still elevated a t  the time of a second visit two weeks later. She was asymptomatic 
during this period except for a residual hemiparesis present before admission $0 
the study. 
Group I H.G. and Group I11 N.B.  manifested mild depression due to deserpi- 
dine. H.G. responded to low doses of methylphenidate hydrochloride. N.B. 
required no treatment, as the depression cleared spontaneously. 
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The numbers of subjects remaining unchanged were similar in the treated 
and placebo groups (Table 2) .  In  each group there were 2 patients whose 
transient cerebral ischemic attacks (present before treatment) continued un- 
changed. Two patients improved in the treated group, and 5 in the placebo 
group. Improvement was mainly due to improved mentation and ambulation. 
General observations 
A pronounced fall in blood pressure did not necessarily cause a dangerous in- 
crease in the recurrence rate of cerebrovascular episodes, and active treatment 
did not invariably reduce the blood pressure. Several patients showed a rise in 
blood pressure despite antihypertensive therapy. The neurologic score sheet 
appeared to be a reliable method for following the patients. A change in overall 
score amounting to 3 points was found to be significant and reproducible by all 
observers independently. An %point decrease in the score was usually regarded 
as sufficient to warrant discontinuing the subject from the study (13). Most 
of the severe neurologic deficits in either medication group occurred in the 
subjects with higher blood pressure levels. 
DISCUSSION 
Three aspects of antihypertensive therapy were considered to be of prime 
importance for analysis: 1) the effect on patients with previous strokes and 
neurologic deficits, 2) the effect on patients with transient ischemic attacks, and 
3) the effect on the mental function of elderly patients with cerebrovascular 
disease. To date, the data are insufficient to provide firm conclusions, but the 
method of study appears feasible. 
Experimental work has shown that neurologic symptoms can be reproduced 
by vasospasm in animals made acutely hypertensive, and that this effect is 
reversible when the blood pressure is lowered (14, 15). Ross Russell (16) re- 
emphasized the occurrence of atherosclerosis of the Circle of Willis in hyperten- 
sive patients and confirmed that miliary microaneurysms are often found; the 
microaneurysms might not be able to withstand even moderate hypertension. Re- 
cent retrospective studies of patients with cerebral infarction indicated that they 
fall into two groups: 1) those with diastolic pressures below 110 mm, who have 
a tendency toward large-vessel stenosis in the neck and the development of mas- 
sive infarction and cystic areas; and 2) those with diastolic pressures above 
110 mm, who have mainly small ischemic softenings, small misdiagnosed in- 
tracerebral hemorrhages and a small proportion of extracranial stenotic lesions 
(17, 18). 
Attempts to induce transient ischemic attacks regularly in patients with TIA 
histories, by provoking hypotension with the use of hexamethonium and a tilt- 
table, have resulted in failure (19). This procedure produced mental changes, 
light-headedness and confusion, but no focal ischemic attacks. Similar results 
were reported when hypotension was induced deliberately during surgery (20). 
Treatment of elderly hypertensive subjects with a reserpine-hydrochlorothiazide 
combination failed to induce significant changes when compared to results in a 
control group (21). 
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Several recently reported studies give some indication of the size of the sample 
and the length of follow-up needed for a conclusive study of this type. A study 
of 158 subjects with cerebrovascular symptoms showed that when strokes 
developed after transient ischemic attacks, the patients had had the warning 
symptoms for an average of eighteen months before the major episode (22). A 
retrospective study (23) demonstrated that in a large group of hypertensive 
patients treated with various antihypertensive agents the occurrence rate of 
neurologic deficits lasting up to one day was 15 per cent, and of deficits lasting 
more than one day, 26.5 per cent; the study lasted twenty-three and a half 
months. 
The Veterans Administration Cooperative Study on Atherosclerosis involved 
a double-blind study of the effects of estrogens in men with cerebral infarction 
caused by atherosclerosis (24). There were 582 patients, followed for an average 
of 16.7 months-287 in the control group and 295 in the treated group. During 
this period there was a 10.3 per cent recurrence of cerebral infarction and an 
11.5 per cent recurrence of transient cerebral ischemia; the rates were not 
significantly different in the two groups. 
A minimum 10 per cent recurrence rate of stroke per year can be predicted. 
If it were postulated that specific treatment would cause a 50 per cent reduc- 
tion in the stroke recurrence rate, then 600 patients would be needed (300 each 
for treatment and control groups) to show a statistical difference (24). The figure 
of 50 per cent reduction is an arbitrary one chosen for the sake of statistical 
projection and does not imply any actual expectation. The present study was 
a planned feasibility trial prior to  a planned cooperative study designed to 
answer the question: “Does the administration of antihypertensive drugs to 
patients with moderate hypertension and cerebrovascular disease affect the 
recurrence rate of cerebrovascular symptoms?” Such a planned national co- 
operative study seems feasible and is now underway (Cooperative Study- 
Cerebrosvascular Disease and Hypertension-~~s-1~01~~-~~-16944-01) . 
SUMMARY 
A controlled double-blind study was conducted on 32 patients with mild to 
moderate hypertension and recent cerebrovascular symptoms. The effects of 
antihypertensive therapy (deserpidine-methyclothiazide combination) on the 
recurrence rate of cerebrovascular symptoms were assessed. During 10.8 months 
of observation there was no difference in the recurrence rate between the two 
groups. The blood pressure response was evaluated a t  seven months; for the 
control group the average reading was 164/99 mm and for the treated group, 
137/83 mm. Two patients receiving antihypertensive therapy showed a side 
effect-minimal depression. The methods developed in the study are described. 
No specific conclusions can be drawn from such a small sample and the 
limited period of observation. Extension of this type of study seems indicated and 
has been shown to be feasible. Our findings are presented as a pilot study of 
a projected cooperative program in which it is planned to use the methods 
developed, to provide sufficient information for defining the value of anti- 
hypertensive therapy in patients with cerebrovascular symptoms. 
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